Hospira Reports First-Quarter 20...(4 $232.1 ...),Health

Date:4/28/2009

4 $232.1 ====== ====== Supplemental Cash Flow Information: Cash paid during the period- Interest $33.1 $38.7 Income taxes, net of refunds $9.9 $6.7 Hospira, Inc. Net Sales by Product Line (Unaudited) (dollars in millions) Three Months Ended March 31, ----------------------------------- % Change % Change at Actual at Constant 2009 2008 Rates Rates ------ ------ ----- ----- Americas-- Pharmaceuticals Specialty Injectables $333.1 $340.7 (2.2)% (0.4)% Other Pharma 137.8 121.9 13.0 % 15.7 % ------ ------ 470.9 462.6 1.8 % 3.8 % Devices Medication Management Systems 121.4 118.1 2.8 % 5.9 % Other Devices 92.4 93.5 (1.2)% 1.1 % ------ ------ 213.8 211.6 1.0 % 3.8 % Total Americas 684.7 674.2 1.6 % 3.9 % Europe, Middle East & Africa-- Pharmaceuticals Specialty Injectables 57.6 78.3 (26.4)% (12.1)% Other Pharma 27.7 36.6 (24.3)% (8.5)% ------ --
'/>"/>

SOURCE Hospira, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Hospira to Host Conference Call for First-Quarter 2009 Results
2. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
3. Hospira Expands Board of Directors
4. Hospira Reports Fourth-Quarter and Full-Year 2008 Results
5. Hospiras Precedex(R) Phase IV Study Published in the Journal of the American Medical Association
6. Hospira to Host Conference Call for Fourth-Quarter 2008 Results and 2009 Projections
7. Hospira to Present at J.P. Morgans 27th Annual Healthcare Conference January 14
8. Hospira Names Ken Meyers to Lead Human Resources
9. Hospira Reports Third-Quarter 2008 Results
10. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
11. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection